Eli Lilly: collaboration agreement with Nektar.
(CercleFinance.com) - Eli Lilly announces a strategic partnership with Nektar Therapeutics to co-develop NKTR-358, a new immunotherapy discovered by Nektar which could treat a number of auto-immune diseases and chronic inflammatory conditions.
Nektar will receive an initial payment of 150 million dollars and will be eligible for up to 250 million in additional development and regulatory stages.
The Indianapolis laboratory will bear 75% of the phase II development costs as well as the entire cost for the commercialisation of the product.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Nektar will receive an initial payment of 150 million dollars and will be eligible for up to 250 million in additional development and regulatory stages.
The Indianapolis laboratory will bear 75% of the phase II development costs as well as the entire cost for the commercialisation of the product.
Copyright (c) 2017 CercleFinance.com. All rights reserved.